🔵 Urology · Prostate Assessment

Prostate Volume Calculator — PSA Density & IPSS

Calculate prostate volume using the ellipsoid formula from TRUS or MRI measurements. Get PSA density, BPH classification, and IPSS urinary symptom score — all in one place.

📐 Ellipsoid Formula 🔬 PSA Density 📋 IPSS Score ⚖️ Prostate Weight 🏥 BPH Classification 💊 Treatment Guidance
🔵

Prostate Volume — Ellipsoid Formula

Volume · PSA Density · Weight · BPH Classification

Enter three orthogonal prostate diameters from TRUS or MRI (in cm). The ellipsoid formula V = L × W × AP × 0.523 is the EAU/AUA gold standard for prostate volume calculation.
Clear
PSA Density (PSAD) = Serum PSA ÷ Prostate Volume. PSAD above 0.15 ng/mL/mL in the PSA grey zone (4–10 ng/mL) raises suspicion for prostate cancer and may guide biopsy decisions.
Clear
The International Prostate Symptom Score (IPSS) — validated 7-question tool for lower urinary tract symptoms (LUTS). Score each symptom over the past month. Score 0–7 = mild, 8–19 = moderate, 20–35 = severe.
Quality of Life — If you had to spend the rest of your life with your urinary symptoms as they are now, how would you feel?
Clear

Prostate Volume — Clinical Reference

Normal Prostate Volume by Age

Prostate volume increases with age due to benign prostatic hyperplasia (BPH). Volume alone does not determine symptoms — the degree of bladder outlet obstruction and patient bother guide treatment decisions. The following ranges are established from population-level TRUS studies.

Age GroupTypical VolumeBPH GradeClinical Relevance
30–40 years15–25 mLNormalBaseline; BPH rarely symptomatic
41–50 years20–30 mLNormal to mildly enlargedEarly BPH may begin; screen if LUTS present
51–60 years25–40 mLMildly enlargedIPSS + TRUS recommended if symptomatic
61–70 years35–55 mLModerately enlargedMedical therapy (alpha-blockers ± 5-ARIs) considered
71–80 years45–80 mLModerately–significantly enlargedAssess for urinary retention, hydronephrosis
80+ years50–100+ mLSignificantly enlargedSurgical planning (HoLEP/TURP) if refractory

PSA Density (PSAD) — Interpretation

PSA density refines the interpretation of total PSA, particularly in the diagnostic grey zone of 4–10 ng/mL where total PSA alone cannot reliably distinguish BPH from prostate cancer. PSAD corrects for the contribution of benign prostatic tissue to PSA secretion.

PSAD (ng/mL/mL)InterpretationRecommendation
<0.10Low — PSA likely from BPHActive surveillance; repeat PSA in 12 months
0.10–0.15BorderlineConsider free/total PSA ratio; counsel and monitor
>0.15Elevated — cancer cannot be excludedBiopsy discussion; MRI prostate (PI-RADS) recommended
>0.25High suspicionPrompt urology referral; targeted biopsy preferred

BPH Treatment by Prostate Volume

Prostate volume guides selection of medical and surgical therapy. The table below reflects EAU and AUA guidelines, which are broadly followed by Indian urologists. Note that alpha-blockers improve symptoms regardless of prostate size; 5-ARIs are volume-dependent and most effective in prostates ≥40 mL.

VolumePreferred Medical TherapySurgical Options
<30 mLAlpha-blocker (tamsulosin 0.4 mg) aloneTUIP if refractory
30–40 mLAlpha-blocker ± 5-ARI (if PSA >1.4)TURP (standard)
40–80 mLCombination: tamsulosin + dutasteride/finasterideTURP, HoLEP, or TUMT
80–150 mLCombination therapy + reassess every 3–6 monthsHoLEP preferred over TURP
>150 mLMedical bridge; surgical planningOpen simple prostatectomy / HoLEP

How Prostate Volume Is Measured

The most accurate method is transrectal ultrasound (TRUS), which allows direct visualisation in sagittal and transverse planes. The probe is placed in the rectum; three orthogonal diameters are measured: anteroposterior (AP), transverse (width), and cranio-caudal (length). MRI prostate is increasingly used and provides superior soft-tissue contrast for simultaneous cancer staging.

Transabdominal ultrasound (TAUS) is less accurate for prostate volume but suitable for screening in primary care. DRE (digital rectal examination) estimates volume subjectively and underestimates large glands; it remains part of the clinical examination but should not replace TRUS for treatment planning.

Ellipsoid Formula — How This Calculator Works

This calculator uses the standard ellipsoid formula: V = Length × Width × AP × 0.523, where 0.523 = π/6 ≈ 0.5236. All measurements are entered in centimetres and the result is given in millilitres (mL), since 1 cm³ = 1 mL. Prostate weight (grams) is derived by multiplying by tissue density (1.05 g/mL), though for practical purposes volume in mL ≈ weight in grams.

Frequently Asked Questions — Prostate Volume

What is the normal prostate volume?

The normal prostate volume in adult men is 20–30 mL. A volume of 30–50 mL is considered mildly enlarged, 50–80 mL moderately enlarged, and above 80 mL significantly enlarged. Prostate volume increases with age, so what is normal at 40 differs from normal at 70. The key clinical question is not just size but whether symptoms (LUTS) are present and whether bladder outlet obstruction is demonstrated.

What is PSA density and when should I calculate it?

PSA density (PSAD) = serum PSA ÷ prostate volume in mL. It is most useful when total PSA is in the grey zone of 4–10 ng/mL, where it is difficult to distinguish BPH from prostate cancer based on total PSA alone. A PSAD above 0.15 ng/mL/mL raises concern for prostate cancer; below 0.10 ng/mL/mL suggests the PSA is explained by BPH. Free/total PSA ratio is complementary — a ratio below 15% also increases cancer suspicion.

What is the IPSS score and what does it mean?

The International Prostate Symptom Score (IPSS) is a validated 7-question questionnaire that quantifies lower urinary tract symptoms (LUTS) over the past month. Scores: 0–7 = mild (watchful waiting), 8–19 = moderate (medical therapy), 20–35 = severe (surgical evaluation). The quality-of-life (bother) question is assessed separately and often drives treatment decisions more than the symptom score alone.

When are 5-alpha reductase inhibitors (finasteride/dutasteride) indicated?

5-ARIs are indicated when prostate volume is ≥40 mL (or ≥30 mL with PSA >1.4 ng/mL). They reduce prostate volume by 20–30% over 6–12 months and reduce the risk of acute urinary retention and need for surgery. They are ineffective in small prostates. The combination of tamsulosin + dutasteride (CombAT study) is superior to either alone for moderate-to-severe LUTS in men with enlarged prostates.

What prostate volume requires surgery?

Surgical intervention is considered when medical therapy fails, when there are absolute indications (acute urinary retention refractory to catheter removal, recurrent UTIs, bladder stones, renal impairment from BPH), or when the patient prefers definitive treatment. TURP is standard for 30–80 mL. HoLEP (holmium laser enucleation of the prostate) has no upper size limit and is preferred for large prostates (>80 mL) in centres where it is available.

How accurate is prostate volume measurement by ultrasound?

TRUS with the ellipsoid formula has a ±10–20% variability compared to pathological weight on prostatectomy specimens. The main sources of error are: examiner experience, probe angle, and patient cooperation. MRI planimetry is more accurate but not routinely used for volume alone. For clinical purposes — treatment planning and PSA density — TRUS ellipsoid volume is sufficient and is the standard of care.

What is considered a large prostate in India?

In Indian men, BPH and LUTS are common from the fifth decade onward. A prostate above 40 mL is considered significantly enlarged for clinical management purposes in most Indian urological practice, with volumes above 80 mL typically requiring discussion of HoLEP or open prostatectomy. Indian men may present later with larger prostates due to delayed health-seeking. PSA levels in Indian men follow similar distributions to Western populations, though formal Indian-specific age-adjusted PSA norms are not yet universally adopted.

Related Clinical Tools

⚠️ For qualified healthcare professionals only. This prostate volume calculator provides clinical decision support only. PSA density and IPSS results must be interpreted in the context of the full clinical picture including DRE, uroflowmetry, post-void residual, and imaging. Always follow current EAU, AUA, and national urology guidelines for individual patient management.